Skip to main content
Erschienen in: Tumor Biology 11/2014

01.11.2014 | Research Article

A functional and protein-protein interaction analysis of neuroepithelial cell transforming gene 1 in hepatocellular carcinoma

verfasst von: Ke Ye, Shi Chang, Jindong Li, Xinying Li, Yuedu Zhou, Zhiming Wang

Erschienen in: Tumor Biology | Ausgabe 11/2014

Einloggen, um Zugang zu erhalten

Abstract

In our previous study, we reported that the expression of neuroepithelial transforming gene 1 (NET1) was increased in hepatocellular carcinoma (HCC) tissues and suggested that NET1 may serve as a novel prognostic predictor and a useful target for HCC therapy. The aim of this study was to determine the role of NET1 in HCC by monitoring the proliferation, migration, invasion, and metastasis of HCC cells in which NET1 has been stably knocked down. Additionally, to provide targets for therapeutic intervention, we aimed to identify the protein which interacts with NET1. NET1 knockdown significantly reduced the migration, invasion, and metastasis of MHCC-97H cells by 44, 65, and 77 %, respectively, while cell proliferation was not significantly altered following NET1 knockdown. During our efforts to find potential NET1 modulators through protein-protein interactions, we identified merlin as a NET1-binding protein in a yeast two-hybrid screen. The interaction between NET1 and merlin was confirmed by co-immunoprecipitation. We found that the levels of NET1 protein decreased along with the increase of merlin levels. Furthermore, we demonstrated that merlin facilitates NET1 ubiquitination via the ubiquitin-proteasome pathway. Taken together, this study suggests that NET1 plays an important role in HCC cell migration, invasion, and metastasis, which are key aspects of HCC progression. Furthermore, merlin may serve as a tumor suppressor for HCC by facilitating ubiquitination of NET1.
Literatur
1.
Zurück zum Zitat Guo X, Wang W, Zhou F, Lu Z, Fang R, Jia F, et al. siRNA-mediated inhibition of hTERT enhances chemosensitivity of hepatocellular carcinoma. Cancer Biol Ther. 2008;7:1555–60.PubMedCrossRef Guo X, Wang W, Zhou F, Lu Z, Fang R, Jia F, et al. siRNA-mediated inhibition of hTERT enhances chemosensitivity of hepatocellular carcinoma. Cancer Biol Ther. 2008;7:1555–60.PubMedCrossRef
2.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
3.
Zurück zum Zitat Cho YK, Rhim H, Noh S. Radiofrequency ablation versus surgical resection as primary treatment of hepatocellular carcinoma meeting the Milan criteria: a systematic review. J Gastroenterol Hepatol. 2011;26:1354–60.PubMed Cho YK, Rhim H, Noh S. Radiofrequency ablation versus surgical resection as primary treatment of hepatocellular carcinoma meeting the Milan criteria: a systematic review. J Gastroenterol Hepatol. 2011;26:1354–60.PubMed
4.
Zurück zum Zitat Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology. 2011;140:1501–12.PubMedCentralPubMedCrossRef Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology. 2011;140:1501–12.PubMedCentralPubMedCrossRef
5.
Zurück zum Zitat Ziol M, Sutton A, Calderaro J, Barget N, Aout M, Leroy V, et al. ESM-1 expression in stromal cells is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma. J Hepatol. 2013;59:1264–70.PubMedCrossRef Ziol M, Sutton A, Calderaro J, Barget N, Aout M, Leroy V, et al. ESM-1 expression in stromal cells is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma. J Hepatol. 2013;59:1264–70.PubMedCrossRef
6.
Zurück zum Zitat Luo X, Xie H, Long X, Zhou M, Xu Z, Shi B, et al. EGFRvIII mediates hepatocellular carcinoma cell invasion by promoting S100 calcium binding protein A11 expression. PLoS One. 2013;8:e83332.PubMedCentralPubMedCrossRef Luo X, Xie H, Long X, Zhou M, Xu Z, Shi B, et al. EGFRvIII mediates hepatocellular carcinoma cell invasion by promoting S100 calcium binding protein A11 expression. PLoS One. 2013;8:e83332.PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Maemura K, Yoshikawa H, Yokoyama K, Ueno T, Kurose H, Uchiyama K, et al. Delta-like 3 is silenced by methylation and induces apoptosis in human hepatocellular carcinoma. Int J Oncol. 2013;42:817–22.PubMedCentralPubMed Maemura K, Yoshikawa H, Yokoyama K, Ueno T, Kurose H, Uchiyama K, et al. Delta-like 3 is silenced by methylation and induces apoptosis in human hepatocellular carcinoma. Int J Oncol. 2013;42:817–22.PubMedCentralPubMed
8.
Zurück zum Zitat Ye K, Wang Z, Zhang G, Liang S. Prognostic significance of neuroepithelial transforming protein 1 in hepatocellular carcinoma. J Invest Surg. 2010;23:163–9.PubMedCrossRef Ye K, Wang Z, Zhang G, Liang S. Prognostic significance of neuroepithelial transforming protein 1 in hepatocellular carcinoma. J Invest Surg. 2010;23:163–9.PubMedCrossRef
9.
Zurück zum Zitat Symons M, Rusk N. Control of vesicular trafficking by Rho GTPases. Curr Biol. 2003;13:R409–18.PubMedCrossRef Symons M, Rusk N. Control of vesicular trafficking by Rho GTPases. Curr Biol. 2003;13:R409–18.PubMedCrossRef
10.
Zurück zum Zitat Rossman KL, Der CJ, Sondek J. GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol. 2005;6:167–80.PubMedCrossRef Rossman KL, Der CJ, Sondek J. GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol. 2005;6:167–80.PubMedCrossRef
11.
Zurück zum Zitat Kawasaki Y, Sato R, Akiyama T. Mutated APC and Asef are involved in the migration of colorectal tumour cells. Nat Cell Biol. 2003;5:211–5.PubMedCrossRef Kawasaki Y, Sato R, Akiyama T. Mutated APC and Asef are involved in the migration of colorectal tumour cells. Nat Cell Biol. 2003;5:211–5.PubMedCrossRef
12.
Zurück zum Zitat Advani AS, Pendergast AM. Bcr-Abl variants: biological and clinical aspects. Leuk Res. 2002;26:713–20.PubMedCrossRef Advani AS, Pendergast AM. Bcr-Abl variants: biological and clinical aspects. Leuk Res. 2002;26:713–20.PubMedCrossRef
13.
Zurück zum Zitat Mizuarai S, Yamanaka K, Kotani H. Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells. Cancer Res. 2006;66:6319–26.PubMedCrossRef Mizuarai S, Yamanaka K, Kotani H. Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells. Cancer Res. 2006;66:6319–26.PubMedCrossRef
14.
Zurück zum Zitat Chan AM, Takai S, Yamada K, Miki T. Isolation of a novel oncogene, NET1, from neuroepithelioma cells by expression cDNA cloning. Oncogene. 1996;12:1259–66.PubMed Chan AM, Takai S, Yamada K, Miki T. Isolation of a novel oncogene, NET1, from neuroepithelioma cells by expression cDNA cloning. Oncogene. 1996;12:1259–66.PubMed
15.
Zurück zum Zitat Leyden J, Murray D, Moss A, Arumuguma M, Doyle E, McEntee G, et al. Net1 and Myeov: computationally identified mediators of gastric cancer. Br J Cancer. 2006;94:1204–12.PubMedCentralPubMedCrossRef Leyden J, Murray D, Moss A, Arumuguma M, Doyle E, McEntee G, et al. Net1 and Myeov: computationally identified mediators of gastric cancer. Br J Cancer. 2006;94:1204–12.PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Sun FX, Tang ZY, Lui KD, Ye SL, Xue Q, Gao DM, et al. Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues. Int J Cancer. 1996;66:239–43.PubMedCrossRef Sun FX, Tang ZY, Lui KD, Ye SL, Xue Q, Gao DM, et al. Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues. Int J Cancer. 1996;66:239–43.PubMedCrossRef
17.
Zurück zum Zitat Lee JY, Kim H, Ryu CH, Kim JY, Choi BH, Lim Y, et al. Merlin, a tumor suppressor, interacts with transactivation-responsive RNA-binding protein and inhibits its oncogenic activity. J Biol Chem. 2004;279:30265–73.PubMedCrossRef Lee JY, Kim H, Ryu CH, Kim JY, Choi BH, Lim Y, et al. Merlin, a tumor suppressor, interacts with transactivation-responsive RNA-binding protein and inhibits its oncogenic activity. J Biol Chem. 2004;279:30265–73.PubMedCrossRef
18.
Zurück zum Zitat Guo X, Stafford LJ, Bryan B, Xia C, Ma W, Wu X, et al. A Rac/Cdc42-specific exchange factor, GEFT, induces cell proliferation, transformation, and migration. J Biol Chem. 2003;278:13207–15.PubMedCrossRef Guo X, Stafford LJ, Bryan B, Xia C, Ma W, Wu X, et al. A Rac/Cdc42-specific exchange factor, GEFT, induces cell proliferation, transformation, and migration. J Biol Chem. 2003;278:13207–15.PubMedCrossRef
19.
Zurück zum Zitat Bennett G, Sadlier D, Doran PP, Macmathuna P, Murray DW. A functional and transcriptomic analysis of NET1 bioactivity in gastric cancer. BMC Cancer. 2011;11:50.PubMedCentralPubMedCrossRef Bennett G, Sadlier D, Doran PP, Macmathuna P, Murray DW. A functional and transcriptomic analysis of NET1 bioactivity in gastric cancer. BMC Cancer. 2011;11:50.PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Minard ME, Kim LS, Price JE, Gallick GE. The role of the guanine nucleotide exchange factor Tiam1 in cellular migration, invasion, adhesion and tumor progression. Breast Cancer Res Treat. 2004;84:21–32.PubMedCrossRef Minard ME, Kim LS, Price JE, Gallick GE. The role of the guanine nucleotide exchange factor Tiam1 in cellular migration, invasion, adhesion and tumor progression. Breast Cancer Res Treat. 2004;84:21–32.PubMedCrossRef
21.
Zurück zum Zitat Minard ME, Ellis LM, Gallick GE. Tiam1 regulates cell adhesion, migration and apoptosis in colon tumor cells. Clin Exp Metastasis. 2006;23:301–13.PubMedCrossRef Minard ME, Ellis LM, Gallick GE. Tiam1 regulates cell adhesion, migration and apoptosis in colon tumor cells. Clin Exp Metastasis. 2006;23:301–13.PubMedCrossRef
22.
Zurück zum Zitat Entschladen F, Drell 4th TL, Lang K, Joseph J, Zaenker KS. Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters. Lancet Oncol. 2004;5:254–8.PubMedCrossRef Entschladen F, Drell 4th TL, Lang K, Joseph J, Zaenker KS. Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters. Lancet Oncol. 2004;5:254–8.PubMedCrossRef
23.
Zurück zum Zitat Xu Y, Sun HC, Tian B, Li Y, Chen J, Chen J, et al. Establishment of green fluorescent protein-expressing hepatocellular carcinoma cell lines with different metastatic potential: relevant models for in vivo monitoring of metastasis and angiogenesis. J Cancer Res Clin Oncol. 2004;130:375–82.PubMedCrossRef Xu Y, Sun HC, Tian B, Li Y, Chen J, Chen J, et al. Establishment of green fluorescent protein-expressing hepatocellular carcinoma cell lines with different metastatic potential: relevant models for in vivo monitoring of metastasis and angiogenesis. J Cancer Res Clin Oncol. 2004;130:375–82.PubMedCrossRef
24.
Zurück zum Zitat Gietz RD, Triggs-Raine B, Robbins A, Graham KC, Woods RA. Identification of proteins that interact with a protein of interest: applications of the yeast two-hybrid system. Mol Cell Biochem. 1997;172:67–79.PubMedCrossRef Gietz RD, Triggs-Raine B, Robbins A, Graham KC, Woods RA. Identification of proteins that interact with a protein of interest: applications of the yeast two-hybrid system. Mol Cell Biochem. 1997;172:67–79.PubMedCrossRef
25.
Zurück zum Zitat Gusella JF, Ramesh V, MacCollin M, Jacoby LB. Neurofibromatosis 2: loss of merlin's protective spell. Curr Opin Genet Dev. 1996;6:87–92.PubMedCrossRef Gusella JF, Ramesh V, MacCollin M, Jacoby LB. Neurofibromatosis 2: loss of merlin's protective spell. Curr Opin Genet Dev. 1996;6:87–92.PubMedCrossRef
26.
Zurück zum Zitat Tsukita S, Yonemura S. ERM (ezrin/radixin/moesin) family: from cytoskeleton to signal transduction. Curr Opin Cell Biol. 1997;9:70–5.PubMedCrossRef Tsukita S, Yonemura S. ERM (ezrin/radixin/moesin) family: from cytoskeleton to signal transduction. Curr Opin Cell Biol. 1997;9:70–5.PubMedCrossRef
27.
Zurück zum Zitat Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol. 2002;3:586–99.PubMedCrossRef Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol. 2002;3:586–99.PubMedCrossRef
28.
Zurück zum Zitat Sun CX, Robb VA, Gutmann DH. Protein 4.1 tumor suppressors: getting a FERM grip on growth regulation. J Cell Sci. 2002;115:3991–4000.PubMedCrossRef Sun CX, Robb VA, Gutmann DH. Protein 4.1 tumor suppressors: getting a FERM grip on growth regulation. J Cell Sci. 2002;115:3991–4000.PubMedCrossRef
29.
Zurück zum Zitat McClatchey AI, Saotome I, Ramesh V, Gusella JF, Jacks T. The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. Genes Dev. 1997;11:1253–65.PubMedCrossRef McClatchey AI, Saotome I, Ramesh V, Gusella JF, Jacks T. The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. Genes Dev. 1997;11:1253–65.PubMedCrossRef
30.
Zurück zum Zitat McClatchey AI, Saotome I, Mercer K, Crowley D, Gusella JF, Bronson RT, et al. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev. 1998;12:1121–33.PubMedCentralPubMedCrossRef McClatchey AI, Saotome I, Mercer K, Crowley D, Gusella JF, Bronson RT, et al. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev. 1998;12:1121–33.PubMedCentralPubMedCrossRef
31.
Zurück zum Zitat Giovannini M, Robanus-Maandag E, van der Valk M, Niwa-Kawakita M, Abramowski V, Goutebroze L, et al. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev. 2000;14:1617–30.PubMedCentralPubMed Giovannini M, Robanus-Maandag E, van der Valk M, Niwa-Kawakita M, Abramowski V, Goutebroze L, et al. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev. 2000;14:1617–30.PubMedCentralPubMed
32.
Zurück zum Zitat Kalamarides M, Niwa-Kawakita M, Leblois H, Abramowski V, Perricaudet M, Janin A, et al. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev. 2002;16:1060–5.PubMedCentralPubMedCrossRef Kalamarides M, Niwa-Kawakita M, Leblois H, Abramowski V, Perricaudet M, Janin A, et al. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev. 2002;16:1060–5.PubMedCentralPubMedCrossRef
Metadaten
Titel
A functional and protein-protein interaction analysis of neuroepithelial cell transforming gene 1 in hepatocellular carcinoma
verfasst von
Ke Ye
Shi Chang
Jindong Li
Xinying Li
Yuedu Zhou
Zhiming Wang
Publikationsdatum
01.11.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 11/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2454-3

Weitere Artikel der Ausgabe 11/2014

Tumor Biology 11/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.